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Diff  use large B cell lymphoma (DLBCL) rep-
resents the most frequent type of B cell non-
Hodgkin lymphoma (B-NHL) in the adult, 
accounting for  40% of all diagnoses (1). 
Based on gene expression profi  le analysis, dis-
tinct subtypes of DLBCL have been identifi  ed, 
which refl  ect the origin from diff  erent stages 
of normal B cell diff  erentiation (2, 3). These 
include the germinal center B cell–like (GCB) 
DLBCL, presumably derived from a GC cen-
troblast, and the activated B cell–like (ABC) 
DLBCL, whose cell of origin is less clear but 
which resembles the expression pattern of a 
subset of GC cells undergoing plasmacytic dif-
ferentiation or of mitogen-activated periph-
eral B cells (2, 3). A third group of DLBCL 
is represented by primary mediastinal large B 
cell lymphomas, postulated to arise from thy-
mic B cells (4, 5), whereas 15–30% of the cases 
remain unclassifi  ed (6). An additional classifi  -
cation, also based on gene expression profi  l-
ing, identifi  ed three discrete subsets defi  ned by 
the expression of genes involved in oxidative 
phosphorylation (OXP), BCR/proliferation 
(BCR), or tumor microenvironment/host in-
fl  ammatory response (HR) (7).
Consistent with this heterogeneity, the ge-
netic lesions associated with DLBCL are also 
diverse and include balanced reciprocal trans-
locations deregulating the expression of BCL6, 
BCL2 and cMYC, gene amplifi  cations, non-
random chromosomal deletions, and aberrant 
somatic hypermutation (8–12). Nonetheless, a 
signifi  cant fraction of DLBCLs remains orphan  The online version of this article contains supplemental material. The online version of this article contains supplemental material.
<doi> 10.1083/jcb.200502204</doi><aid>200502204</aid>Inactivation of the PRDM1/BLIMP1 gene 
in diff  use large B cell lymphoma
Laura Pasqualucci,1,2 Mara Compagno,1,2 Jane Houldsworth,3 
Stefano Monti,4 Adina Grunn,1,2 Subhadra V . Nandula,1,2 
Jon C. Aster,5 Vundavally V . Murty,1,2 Margaret A. Shipp,6 
and Riccardo Dalla-Favera1,2
1Institute for Cancer Genetics and 2The Herbert Irving Comprehensive Cancer Center, Columbia University, New York, 
NY 10032
3Laboratory of Cancer Genetics and the Department of Medicine, Memorial Sloan-Kettering Cancer Center, 
New York, NY 10021
4Broad Institute, Massachusetts Institute of Technology, Cambridge, MA 02141
5Department of Pathology, Brigham and Women’s Hospital and 6Dana-Farber Cancer Institute, Harvard Medical School, 
Boston, MA 12115
PR domain containing 1 with zinc fi  nger domain (PRDM1)/B lymphocyte–induced matura-
tion protein 1 (BLIMP1) is a transcriptional repressor expressed in a subset of germinal 
center (GC) B cells and in all plasma cells, and required for terminal B cell differentiation. 
The BLIMP1 locus lies on chromosome 6q21-q22.1, a region frequently deleted in B cell 
lymphomas, suggesting that it may harbor a tumor suppressor gene. We report here that 
the BLIMP1 gene is inactivated by structural alterations in 24% (8 out of 34) activated 
B cell–like diffuse large cell lymphoma (ABC-DLBCL), but not in GC B cell–like (n = 0/37) 
or unclassifi  ed (n = 0/21) DLBCL. BLIMP1 alterations included gene truncations, nonsense 
mutations, frameshift deletions, and splice site mutations that generate aberrant tran-
scripts encoding truncated BLIMP1 proteins. In all cases studied, both BLIMP1 alleles were 
inactivated by deletions or mutations. Furthermore, most non–GC type DLBCL cases 
(n = 20/26, 77%) lack BLIMP1 protein expression, despite the presence of BLIMP1 mRNA. 
These results indicate that a sizable fraction of ABC-DLBCL carry an inactive BLIMP1 gene, 
and suggest that the same gene is inactivated by epigenetic mechanisms in an additional 
large number of cases. These fi  ndings point to a role for BLIMP1 as a tumor suppressor 
gene, whose inactivation may contribute to lymphomagenesis by blocking post–GC differ-
entiation of B cells toward plasma cells.
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of any specifi  c genetic  changes and, in particular, no tumor 
suppressor genes have been identifi   ed, whose inactivation 
contributes to the pathogenesis of primary DLBCL.
One common alteration found in all B-NHL, including 
DLBCL, is represented by deletions aff  ecting various por-
tions of the long arm of chromosome 6 (10). Of these, 6q21 
deletions are most frequently associated with high-grade 
lymphomas, such as DLBCL, where they may play a major 
pathogenetic role because they sometimes appear as the sole 
karyotypic abnormality present at diagnosis and correlate 
with poor prognosis (13, 14). Based on these observations, it 
has been proposed that this region may harbor a tumor sup-
pressor locus. Among the genes mapped to band 6q21, PR 
domain containing 1 with zinc fi  nger domain (PRDM1)/B 
lymphocyte–induced maturation protein 1 (BLIMP1) repre-
sents a good candidate because it encodes for a transcriptional 
repressor (15) that, in the B cell lineage, is expressed specifi  -
cally in plasma cells and in a subset of GC centrocytes with 
plasmacytoid markers (16, 17). BLIMP1 is required for ter-
minal diff  erentiation of GC B cells into plasma cells, which it 
promotes by blocking the expression of genes implicated in 
B cell receptor signal and cell proliferation (18, 19).
In the present study, we investigated whether the struc-
ture and/or function of the BLIMP1 gene was altered in a 
panel of DLBCLs representative of the various phenotypic 
subtypes. We report the frequent inactivation of BLIMP1 
specifi  cally in ABC-DLBCL, suggesting an important role 
for this gene in the pathogenesis of this lymphoma subtype.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
To test whether genetic alterations aff  ecting BLIMP1 are in-
volved in DLBCL pathogenesis, we performed mutational 
analysis of the BLIMP1 gene in 134 DLBCL cases, including 
20 cell lines and 114 primary biopsies. 92 samples had been 
previously characterized by gene expression profi  ling and 
comprised 34 ABC, 37 GCB, and 21 unclassifi  ed DLBCL. 
Southern blot analysis was also performed in a subset of 30 
cases (12 ABC, 10 GCB, and 8 unclassifi  ed) to examine the 
presence of gross gene rearrangements across an  20-Kb 
  region, spanning the promoter and exons 1–4 (Fig. 1 A).
Rearrangement of the BLIMP1 gene in the Ly3 cell line
BLIMP1 gene rearrangements were found in one of 30 
  DLBCL DNAs tested, represented by the ABC-DLBCL cell 
line Ly3. Fig. 1 B shows a Southern blot analysis of genomic 
DNA from Ly3 and a control sample; aberrant restriction 
fragments were detected in all Ly3 digests hybridized with an 
exon 2 probe, as well as in the XmaI digest hybridized with 
an exon 3 probe, consistent with a rearrangement within the 
EcoRI–SpeI region spanning exon 2 (Fig. 1 A). Moreover, 
Figure 1.  Biallelic inactivation of BLIMP1 by rearrangement and 
deletion in the Ly3 cell line. (A) BLIMP1 genomic locus: fi  lled and 
empty boxes represent coding and noncoding exons, respectively. Arrows 
correspond to alternative transcription initiation sites, and triangles 
below the map depict the primers used for mutational analysis. 
  Restriction sites for Southern blot analysis are also indicated (X, XmaI; 
RI, EcoRI; S, SpeI) and aligned to the predicted restriction fragments; 
a   vertical arrow points to the breakpoint region, as determined by re-
striction enzyme digestion. (B) Southern blot analysis of Ly3 and control 
DNA (N) using the probes indicated. (C) Dual-color FISH analysis of Ly3 
cells hybridized with BLIMP1 probes (green, arrow) and a chromosome 6 
  centromeric probe (red). (D) Chromatograms of BLIMP1 exon 5 genomic 
sequences. A 2-bp deletion, introducing a premature stop codon, 
is   present in Ly3.JEM VOL. 203, February 20, 2006  313
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the WT allele could not be detected in Ly3, indicating its 
  deletion. Dual-color fl  uorescence in situ hybridization (FISH) 
analysis confi  rmed the loss of one copy of the BLIMP1 locus 
in this tetraploid cell line (Fig. 1 C), whereas the remaining 
BLIMP1 signal maps to chromosome 6, suggesting that the 
aberrant fragment observed by Southern analysis is the result 
of an intrachromosomal rearrangement rather than of a trans-
location. As a consequence, the BLIMP1α transcript cannot 
be produced, a result confi  rmed by RT-PCR and Northern 
blot analysis (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20052204/DC1). In addition, a 2-bp dele-
tion was found within the exon 5 sequences, leading to a 
premature stop codon and, therefore, abrogating the coding 
potential of the remaining BLIMP1β transcript (Fig. 1 D). 
Consistently, no protein expression was detected by Western 
blot analysis (unpublished data).
Consensus splice site mutations
In three cases (Ly10, no. 289, and no. 359), a recurrent nu-
cleotide change was found within the consensus splice do-
nor site at the exon 2–intron 2 junction (see Fig. 2 A for 
a representative sample). RT-PCR and sequencing analysis 
using primers specifi   c for the two known BLIMP1 tran-
scripts could be performed in two out of the three cases and 
demonstrated the presence of an aberrant BLIMP1α mRNA 
retaining 100 nucleotides from intron 2, leading to a pre-
mature translation termination signal (Fig. 2, B–D). In both 
tumors, inactivation of the second allele, a result of deletion 
(Ly10) or mutation (no. 359), was documented by FISH 
analysis and sequencing of cloned PCR products, respec-
tively (Fig. 2 E and Table S1, available at http://www.jem.
org/cgi/content/full/jem.20052204/DC1).
One additional primary biopsy (no. 438) displayed a G→A 
mutation aff  ecting the consensus splice acceptor site at the 
intron 2–exon 3 junction (Fig. 3 A) and predicting an abnor-
mal splicing. This sample expressed an aberrant transcript as a 
result of in-frame loss of the gene exon 3 (Fig. 3, B and C) 
that encodes for most of the PR domain, a region shown to 
contribute to the BLIMP1 activity as a transcriptional repres-
sor (20, 21). RT-PCR and sequencing analysis also showed 
that the second allele was lost, consistent with a monosomy 
6 detected by FISH analysis (Table S1).
Frameshift deletions and nonsense mutations
In four additional primary biopsies, frameshift deletions lead-
ing to premature stop codons were observed in exon 4 (no. 
359), exon 5 (no. 295 and 284), and exon 7 (no. 340), 
whereas a nonsense mutation was detected in the cDNA se-
quence corresponding to exon 5 of no. 251 (no genomic 
DNA was available for this case). As a consequence, severely 
truncated polypeptides of 119–215 amino acids that have lost 
functionally relevant domains (including the PR, proline 
Figure 2.  Splice donor site mutation and loss of the second allele 
in Ly10. (A) Sequencing analysis of genomic DNA from Ly10 and a con-
trol sample. The arrow indicates a single bp substitution affecting the 
splice donor site. (B) Schematic diagram of the BLIMP1 gene and its two 
transcripts; primers used for RT-PCR amplifi  cation (triangles) are posi-
tioned below the maps. (C) Aberrant BLIMP1α transcripts in Ly10 (arrow), 
as compared with the U266 multiple myeloma cell line. GAPDH controls 
for loading. (D) Sequencing of the RT-PCR–generated product reveals 
aberrant splicing as a result of retention of intronic sequences. (E) Dual-
color FISH analysis was performed as described in Fig. 1 C. Arrows point 
to the BLIMP1 signal.314  BLIMP1 MUTATIONS IN ABC-DLBCL | Pasqualucci et al.
rich, and zinc fi  nger DNA-binding domains) and are most 
likely inactive, are produced in no. 251, 284, 295, and 359 
(Fig. 4). The remaining case (no. 340) is predicted to encode 
a truncated protein of 603 amino acids, lacking the three 
COOH-terminal zinc fi  nger domains and the COOH-ter-
minal acidic domain (Fig. 4). Although zinc fi  ngers 1 and 2 
have been shown to be suffi   cient for sequence specifi  c DNA 
binding (22), artifi  cial mutants carrying truncation of the 
COOH-terminal acidic domain display impaired repression 
activity and may therefore also interfere with the normal 
BLIMP1 function (21).
Notably, sequencing analysis of the BLIMP1α transcript 
after amplifi  cation and cloning in no. 359, which carries a 
second inactivating event in the exon 2 splice donor site (see 
previous paragraph section and Fig. 4 B), documented that 
the mutations were distributed in two separate alleles, thereby 
leading to biallelic inactivation of the gene. FISH analysis was 
performed on two of the remaining cases, for which material 
was available, and revealed deletion of one BLIMP1 allele, as 
a result of loss of the entire chromosome 6, in no. 284 (Table 
S1). Conversely, three copies of chromosome 6 were de-
tected in no. 251; however, the mutant allele was overrepre-
sented in the RT-PCR product amplifi  ed from this primary 
biopsy, suggesting that the WT allele is lost or silenced in the 
tumor population, and that the residual WT sequences derive 
from contaminating normal cells. In the former scenario, the 
Figure 3.  Mutation of the BLIMP1 intron 2 splice acceptor site 
and loss of WT allele in a primary DLBCL. (A) Chromatograms of 
  genomic DNA from DLBCL no. 438 (and a control sample). The residual 
WT sequences are likely a result of normal cells contaminating the biopsy 
because this case carries a monosomy 6. (B) Gel electrophoresis of RT-PCR 
Figure 4.  Distribution and features of BLIMP1 mutations in 
ABC-DLBCL. (A) Schematic representation of the human BLIMP1 pro-
tein with its functional domains. Color-coded symbols depict distinct 
types of alterations leading to BLIMP1 inactivation as detailed in 
B. Aci, acidic domain; PR, positive regulatory domain; Pro-rich, proline 
rich domain.
products obtained from the indicated samples. A shorter BLIMP1α 
  transcript and absence of the WT allele are observed in case no. 438. 
(C) Sequencing analysis of the RT-PCR product from no. 438 reveals the 
in-frame loss of exon 3.JEM VOL. 203, February 20, 2006  315
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trisomy 6 may result from loss of the chromosome carrying 
the WT allele and triplication of the chromosome carrying 
the mutant allele.
Finally, fi  ve samples displayed single bp substitutions lead-
ing to amino acid changes in the gene exon 5 (n = 3) and exon 
7 (n = 2) (unpublished data). Because no matched normal 
DNA was available from these samples, we cannot determine 
whether the changes represent rare germline polymorphisms 
or somatic mutations that may aff  ect the BLIMP1 function.
In summary, BLIMP1 structural alterations clustered 
within the NH2-terminal half of the protein in 8/9 mutated 
cases and predict severely truncated polypeptides that will not 
be functional or may act in a dominant-negative fashion. 
Moreover, biallelic inactivation of the gene as a clonally rep-
resented event was demonstrated in all cases studied, indicat-
ing that in these tumors BLIMP1 is inactivated by the classic 
“two-hit” mechanism previously described for several tumor 
suppressor genes (23). Accordingly, immunostaining with 
BLIMP1-specifi  c antibodies documented the absence of pro-
tein expression in all mutated cases tested, despite the pres-
ence of BLIMP1 mRNA (Table S1 and not depicted).
BLIMP1 inactivation is restricted to the ABC type of DLBCL
To determine whether BLIMP1 alterations are associated 
with specifi  c DLBCL subtypes, we examined their distribu-
tion in relation to both cell of origin (3, 6) and comprehen-
sive consensus clustering–based classifi   cations (7). No 
preferential distribution was observed with respect to the lat-
ter (alterations were found in 4 BCR, 3 HR, and 1 OXP 
case). However, all the mutated cases segregated with the 
ABC phenotype (n = 8/34, corresponding to 24%; the non-
profi  led case also displayed a non-GC phenotype, based on 
immunohistochemical analysis), whereas mutations were 
never observed in 37 GCB-type (P < 0.01, χ2 test) and 21 
“unclassifi  ed” DLBCLs (P = 0.01). Thus, BLIMP1 struc-
tural alterations represent a common and specifi  c lesion in 
ABC-DLBCL.
Lack of BLIMP1 protein expression in ABC-DLBCL
Defective expression of a tumor suppressor protein can occur 
by gene deletion/mutation as well as epigenetic inactivation 
caused by promoter methylation, ineffi   cient translation, or 
enhanced protein degradation (23). A recent study reported 
the lack of BLIMP1 protein in 95% of DLBCL, but did not 
distinguish between lymphoma subtypes (17). Thus, we per-
formed immunohistochemical analysis of BLIMP1 expres-
sion in 58 primary biopsies, including 44 from the previous 
study, which were classifi  ed into GCB and non-GCB ac-
cording to Hans et al. (24). BLIMP1 was completely absent 
in 29/32 (91%) GCB-DLBCL, as expected because they are 
thought to derive from GC B cells that do not normally ex-
press BLIMP1; however, 20/26 (77%) non-GCB DLBCLs, 
including 4/4 unmutated cases, were also negative, despite 
the fact that ABC-DLBCLs appear to derive from cells that 
normally express markers of plasmacytic diff  erentiation, such 
as IRF4 and BLIMP1. Indeed, IRF4, the transcription factor 
consistently coexpressed with BLIMP1 in normal GC B cells 
(16, 17), was present in 16/20 (80%) BLIMP1− cases 
(IRF4+BLIMP1+ cases: 6/26, 23%; IRF−BLIMP1− cases: 
4/26, 15%) (Fig. 5). The lack of BLIMP1 expression in most 
ABC-DLBCL was also surprising in view of the following 
facts: (a) BLIMP1 mRNA can be detected in a sizable frac-
tion of ABC-DLBCL by gene expression profi  ling ( 60% in 
the present cohort; also, see available databases from refer-
ences 2 and 7) (Fig. S1 A); (b) the transcripts detected in tu-
mor biopsies most likely derive from tumor cells rather than 
from contaminating normal T cells, which also express 
BLIMP1 (17) because they were present in DLBCL cases 
Figure 5.  Lack of BLIMP1 protein expression in most non-GCB 
DLBCL. Double immunofl  uorescence staining for IRF4 (red) and BLIMP1 
(green) in human tonsil (left) and two representative ABC-DLBCL cases (mid-
dle: IRF4+/BLIMP1+; right: IRF4+/BLIMP1−).316  BLIMP1 MUTATIONS IN ABC-DLBCL | Pasqualucci et al.
purifi  ed by CD19 enrichment (Fig. S1 B); and (c) BLIMP1 
mRNA is expressed in two out of two ABC-DLBCL lines 
carrying inactivating mutations (Fig. S1 C). These observa-
tions suggest that most ABC-DLBCLs express the BLIMP1 
mRNA, but fail to express the BLIMP1 protein. Because the 
fraction of cases lacking BLIMP1 protein expression (77%) 
signifi  cantly exceeds that of cases with inactivating mutations 
(24%), it is likely that additional mechanisms, including de-
fects in protein translation or stability, contribute to BLIMP1 
inactivation in a higher fraction of ABC-DLBCL.
Conclusions
The results herein indicate that BLIMP1 is inactivated by a 
classic two-hit mechanism in  25% of ABC-DLBCL and 
suggest that the BLIMP1 protein is abnormally missing in an 
additional sizable fraction of cases. These fi  ndings strongly 
suggest that BLIMP1 may act as a tumor suppressor gene, 
whose loss of function may contribute to the pathogenesis of 
ABC-DLBCL. Experiments aimed at directly demonstrating 
the tumor suppressor function of BLIMP1 by reintroduc-
tion of the BLIMP1 gene into BLIMP1-null DLBCL cell 
lines (Ly3, Ly10) were inconclusive because they showed 
a generalized apoptotic eff  ect in both BLIMP1-null and 
control BLIMP1-positive B cell lines (unpublished data). 
These results are consistent with previous studies reporting 
the toxicity of exogenous BLIMP1 expression in multiple 
cell types (25, 26). Thus, ongoing studies monitoring lym-
phoma development in mice with conditional inactivation of 
BLIMP1 in GC B cells should provide defi  nitive demonstra-
tion of the role of this gene as a tumor suppressor in the B 
lineage in vivo. Nonetheless, the substantial in vitro and in 
vivo evidence indicating that BLIMP1 is required for plasma-
cytic diff  erentiation (18, 19) strongly suggests that BLIMP1 
inactivation may contribute to lymphomagenesis by block-
ing post-GC B cell diff  erentiation. Notably, translocations 
deregulating the BCL6 gene, a transcriptional repressor re-
quired for GC formation and down-regulated upon plasma-
cytoid diff  erentiation, were never found in BLIMP1 mutated 
DLBCLs (n = 0/7), but were restricted to unmutated cases 
(n = 8/62, 13%). Because it has been proposed that BCL6 
may block terminal B cell diff  erentiation (27), these fi  ndings 
suggest that BCL6 deregulation and BLIMP1 inactivation 
may represent alternative pathogenetic mechanisms, both 
leading to a block in post-GC diff  erentiation and, ultimately, 
to lymphomagenesis.
MATERIALS AND METHODS
Cell lines. The following DLBCL cell lines were used in the study: OCI-Ly1, 
OCI-Ly3, OCI-Ly4, OCI-Ly7, OCI-Ly8, OCI-Ly10, OCI-Ly18, RC-K8, 
VAL, SUDHL-4, SUDHL-5, SUDHL-6, SUDHL-7, SUDHL-8, SUDHL-
10, HT, DB, TOLEDO, WSU, and FARAGE. Cells were maintained in 
IMDM supplemented with 10% FCS. The Ly10 line was cultured in IMDM 
with 20% heparinized human plasma and 55 μM β-mercaptoethanol.
Tumor samples and classifi  cation. Primary biopsies from 114 newly di-
agnosed DLBCL patients were obtained from the archives of the Depart-
ments of Pathology at Columbia University and Memorial Sloan-Kettering 
Cancer Center (MSKCC), and an additional recently described multi-insti-
tutional series (7). The study was approved by the Institutional Review 
Board Committee of Columbia University, the Dana Farber Cancer Insti-
tute, and MSKCC. 92 samples (including the 20 cell lines and 72 primary 
cases) had been previously characterized by gene expression profi  ling using 
the Aff  ymetrix Gene Chip microarray system and were classifi  ed as GCB 
(n = 37), ABC (n = 34), and other (not otherwise specifi  ed; n = 21) as de-
scribed previously (6, 7). Selection of the 92 cases was based on the availabil-
ity of genomic DNA obtained from the same biopsy simultaneously with 
RNA extraction.
DNA extraction, amplifi  cation, and sequencing. Genomic DNA from 
134 DLBCL samples was extracted according to standard methods. The oli-
gonucleotides used for amplifi  cation of the BLIMP1 exons are reported in 
Table S2 (available at http://www.jem.org/cgi/content/full/jem.20052204/
DC1). Purifi  ed amplicons were sequenced directly from both strands and 
compared with the corresponding germline sequences (NM_001198 for 
BLIMP1α and NM_182907 for BLIMP1β) using the Mutation Surveyor 
Version 2.41 software (Soft Genetics LLC). Where needed, additional inter-
nal primers were used and their sequences are available upon request. Muta-
tions were confi  rmed on independent PCR products and changes due to 
germline polymorphisms, as verifi  ed by analysis of matched normal DNA, 
were excluded.
Southern blot analysis. High-molecular weight DNA (5 μg) was digested 
with the appropriate restriction endonucleases, electrophoresed on a 0.8% 
agarose gel, and transferred overnight to Duralose fi  lters (Stratagene) accord-
ing to standard methods. Filters were sequentially hybridized with probes 
specifi  c to the BLIMP1 exon 2 and exon 3.
RNA extraction, RT-PCR, and Northern blot analysis. Total RNA 
was isolated by TRIzol (Invitrogen) according to the manufacturer’s 
instructions. For RT-PCR analysis, 1 μg of total RNA was retrotranscribed 
using the Superscript Double Stranded cDNA Synthesis kit (Invitrogen) and 
1/20 of the reaction served as template for amplifi  cation of the BLIMP1α 
and BLIMP1β cDNAs, using specifi  c oligonucleotides (Table S2); glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) served as internal control. 
Northern blot analysis was performed by standard methods, using the fol-
lowing radio-labeled probes: human BLIMP1 cDNA (exons 5–7), full-
length IRF4 cDNA, BCL6 cDNA, and GAPDH.
FISH. Two PAC clones (RP1-101M23 and RP1-134E15) spanning the 
BLIMP1 gene were obtained from BACPAC Resources at http://bacpac.
chori.org. DNA was labeled by nick-translation using spectrum green dUTP 
fl  uorochrome (Vysis). A Spectrum red-labeled centromeric probe (Vysis) 
was used to enumerate chromosome 6. Chromosome preparations were 
made from lymphoma cell lines using standard methods. 4–10-μm-thick tis-
sue sections were obtained from formalin-fi  xed paraffi   n or frozen archival 
tissues cut onto adhesive-coated slides. Paraffi   n-sections were baked over-
night at 60°C and frozen sections were fi  xed in 3:1 methanol:acetic acid 
  before hybridization. Both paraffi   n and frozen sections were subjected to 
protease treatment using paraffi   n pretreatment kit (Vysis). FISH was per-
formed by standard methods and hybridization signals were scored on at least 
20 metaphase spreads or 200 interphase nuclei on DAPI-stained slides. The 
sensitivity of the approach was determined by performing the same analysis 
on analogous sections from normal tonsils, which demonstrated loss of the 
6q21 signal in 5–7% of the cells and monosomy 6 (i.e., loss of both 6q21 and 
a chromosome 6 centromeric probe) in 13–26% of the cells. Cases were di-
agnosed as deleted if the fraction of cells showing the deletion was >50%.
Tissue microarray, immunohistochemistry, and immunofl  uores-
cence staining. The construction of the DLBCL tissue microarray and the 
protocols for immunohistochemical and double-immunofl  uorescence stain-
ing are described in detail elsewhere (17). Cases were scored as positive if 
≥30% tumor cells were stained by the corresponding antibody and classifi  ed JEM VOL. 203, February 20, 2006  317
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into GCB and non-GCB DLBCL based on expression of CD10, BCL6, and 
IRF4 (24).
Online supplemental material. Fig. S1 shows expression of BLIMP1 
mRNA in most ABC-DLBCL. Table S1 shows biallelic inactivation of 
BLIMP1 in mutated DLBCL cases. Table S2 reports the sequence of the 
primers used for amplifi  cation of BLIMP1 from genomic DNA and cDNA. 
Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20052204/DC1.
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